Aurora Cannabis (TSE:ACB) Given New C$8.50 Price Target at ATB Capital

Aurora Cannabis (TSE:ACB) had its price objective dropped by investment analysts at ATB Capital from C$9.00 to C$8.50 in a report released on Thursday,BayStreet.CA reports. The firm presently has an “outperform” rating on the stock. ATB Capital’s price objective suggests a potential upside of 35.14% from the company’s current price.

Aurora Cannabis Stock Up 0.5%

Shares of ACB stock traded up C$0.03 during trading hours on Thursday, reaching C$6.29. The company had a trading volume of 162,344 shares, compared to its average volume of 576,979. Aurora Cannabis has a 12 month low of C$4.95 and a 12 month high of C$9.90. The company has a debt-to-equity ratio of 18.72, a current ratio of 3.42 and a quick ratio of 2.48. The company has a market cap of C$355.86 million, a price-to-earnings ratio of -6.17 and a beta of 1.11. The business has a fifty day simple moving average of C$6.84 and a 200-day simple moving average of C$6.83.

Aurora Cannabis (TSE:ACB) last issued its quarterly earnings results on Wednesday, November 5th. The company reported C($0.91) EPS for the quarter. Aurora Cannabis had a negative net margin of 22.55% and a negative return on equity of 8.36%. The business had revenue of C$90.37 million for the quarter. On average, research analysts expect that Aurora Cannabis will post -0.22 earnings per share for the current fiscal year.

Aurora Cannabis Company Profile

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.